Sabinsa granted patent in Mexico for hair health formulation

Photo © AdobeStock.com/diego cervo

Sabinsa (East Windsor, NJ) was granted a new patent granted in Mexico, MX355546, for a composition comprising 10% w/w of 1-O-galloyl-β-D-glucose (β-glucogallin), specifically isolated from Emblica officinalis (Saberry) and a concentrate from the liquid endosperm of Cocos nucifera (Cococin) and selenopeptides. The composition protects the dermal papilla cells—specialized mesenchymal cells that exist at the bottom of hair follicles and play pivotal roles in hair formation, growth, and cycling. 

Protecting the dermal papilla cells from UV-induced damage helps to maintain them in numbers conducive to hair growth. The numbers of live dermal papilla cells are maintained at a level of 95% or more when the dermal papilla cells are exposed to UVB radiation levels in the range of from 0.8 J/cm2 to 1.0 J/cm2.

A recent open-label clinical trial evaluated the efficacy and safety of Sabinsa’s hair serum in healthy adult male and female subjects. After 90 days of application, there was a significant improvement in hair growth rate, hair density, vellus hair density, and terminal hair density in comparison to baseline. There was also a significant reduction in hair fall with bulb and without bulb, and hair thinning.¹

“Preparations to stimulate hair growth are in high demand, and it’s past time for there to be a natural alternative in this category,” said Muhammed Majeed, PhD, founder and chairman of Sabinsa, in a press release. “We’re pleased that the evidence we presented was compelling enough to be granted this latest patent.”

Referene

1. Majeed M et al. “Clinical study to evaluate the efficacy and safety of a hair serum product in healthy adult male and female volunteers with hair fall” Clinical, Cosmetic and Investigational Dermatology, vol. 13 (2020):691–700